key: cord-0971897-jsqn8j73
authors: Laaribi, Ilyass; Mimouni, Hamza; Bouayed, Zakaria; Aidouni, G.H.I.Z.L.A.N.E.E.L.; Berrichi, Samia; Bahouh, Choukri; Bkiyar, Houssam; Housni, Brahim
title: Bilateral spontaneous pneumothorax in critically-ill COVID-19 infants: About two cases
date: 2021-12-06
journal: Ann Med Surg (Lond)
DOI: 10.1016/j.amsu.2021.103172
sha: 68c2b5ac4bfee8f79a81a0960f9df47af1ce373f
doc_id: 971897
cord_uid: jsqn8j73

INTRODUCTION: COVID-19 is an emerging infection, it is the first large-scale pandemic of the 21st century. Several complications have been described during this infection but spontaneous pneumothorax remains an uncommon complication, even more so in infants. CLINICAL PRESENTATION: We report two cases of a 9-month-old and 18-month-old males admitted to our department for the management of an acute respiratory distress due to a COVID-19 infection associated to a spontaneous pneumothorax successfully drained. While one patient had a favorable outcome, the other was readmitted to our department for the management of a septic shock secondary to a urinary tract infection with a deadly outcome. DISCUSSION: In this paragraph we describe known causes behind spontaneous pneumothorax, before detailing the different pathogenesis hypotheses linking pneumothorax to COVID-19, all while comparing data to the literature related to the adult population. CONCLUSION: Spontaneous pneumothorax is a serious complication associated with severe COVID-19 that can occur in infants and must be considered in the event of a respiratory aggravation or a persistent hypoxia.

COVID-19 is an emerging infection, it is the first large-scale pandemic of the 21st century, since its appearance in Wuhan in December 2019 1 , it has raised substantial concerns fueled by the disease's rapid progression throughout the World warranting its designation as a Public Health Emergency of International Concern by the World's Health Organization on January 2021. To this day according the official the WHO's official COVID-19 dashboard there have been 263 563 622 confirmed cases of COVID-19, including 5 232 562 deaths to this day 2 . Thousands of cases of infected children have been reported. However, the severity and the mortality rate remain low compared to the adult population 3 .

Spontaneous pneumothorax is a rare complication of COVID-19 in adults, as only few cases have been reported 4, 5 . This complication is even rarer in children. To this day, no cases of spontaneous pneumothorax in infants have been reported, we present 2 cases of infants with a spontaneous pneumothorax associated with a COVID-19 infection. A 9-month-old male was admitted to the pediatric emergency department for a respiratory distress evolving for 5 days associated to a fever. His mother had tested positive for COVID-19 a week earlier. On admission the infant was conscious, hypotonic, febrile at 39°C, tachycardic at 185 bpm, and tachypneic at 77 cpm. His oxygen saturation was 70% on ambient and 88% under 8L/min of oxygen. A decrease of the vesicular murmurs was noted bilaterally along with signs of respiratory distress. The patient had a history of epilepsy under treatment since the age of 4 months-old. CXR showed a left pneumothorax with foci of condensation (Figure 1a) , a chest-CT was carried out revealing a large pneumothorax bilaterally, and a bilateral interstitial alveolar pneumonitis with posterior consolidation (Figure 1b) . Laboratory tests showed a white blood count (WBC) of 7020/mm 3 (a 600/mm 3 lymphocytes), D-dimers at 1.22 mg/L, C reactive protein (CRP) elevated at 111 mg/L, Lactate Dehydrogenase (LDH) at 1718 U/L and ferritin level at 2000 µg/L, interleukin 6 at 138 pg/ml. A SARS-CoV-2 RT-PCR test performed on a nasopharyngeal swab the next day came back positive. The pneumothorax was drained using a bilateral chest tubes each connected to a single-bottle system, medical treatment consisted of dexamethasone 0,15 mg/kg/day and Amoxicillin/Clavulanic Acid 80mg/kg/day. The regression and ultimately the disappearance of the pneumothorax was assessed using pleural ultrasonography, the drains were removed after 5 days, during which the patient was gradually weaned off oxygen and discharged within the 8 th day of hospital stay.

An 18-month-old male infant, with no medical history other than a circumcision 2 weeks prior, with no notion of COVID-19 infection in the entourage, was admitted to the pediatric emergency department for a respiratory distress. The mother reported a very severe dry cough evolving for 2 days and a fever persistent despite symptomatic treatment. On admission, the infant was cyanotic, hypotonic, and tachypneic at 85cpm, with intercostal, suprasternal indrawing and thoraco-abdominal rocking, his arterial oxygen saturation was 65% on ambient air and 87% under 10L/min of oxygen. Complete blood count showed elevated WBC (15800/mm 3 ) with lymphopenia 570/mm 3 ; elevation of C-reactive protein (220 mg/L), Ferritin level (1052 μ/L), LDH (1612 U/L) and US troponin (183 ng/mL) with D-dimers at 3.15 mg/L. SARS-Cov-2 RT-PCR was performed coming back positive. CXR did not reveal any abnormalities (figure 2a). Chest-CT revealed an alveolar-interstitial pneumopathy along with a large bilateral anterior pneumothorax (figure 2b) which was drained promptly also using bilateral chest tubes each connected to a single-bottle system.

Medical treatment consisted of dexamethasone 0.15mg/kg/day and Amoxicillin/Clavulanic Acid 80mg/kg/day. The infant drains were removed three days later. The patient was transferred to pediatrics on the following day, however, on the 7 th day of hospitalization he developed a urinary tract infection complicated by a refractory septic shock warranting a re-admission to our department, but died shortly thereafter.

Spontaneous pneumothorax can be secondary to an underlying pulmonary pathology such as chronic obstructive pulmonary disease with emphysema, cystic fibrosis, tuberculosis, lung cancer, pneumocystis associated with HIV J o u r n a l P r e -p r o o f jiroveci pneumonia (PJP) or other cystic pneumonitis, it can also be a primary pneumothorax in the absence of any pulmonary disease 6, 7 , which was the case in our 2 patients.

Unlike the number of pneumothorax cases complicating COVID-19 in adults reported to the literature 8, 9 , no cases have been reported in infants.

No causal link has been proven between the occurrence of pneumothorax during COVID-19 to this day and its pathogenicity is still yet to be established. There are several possible hypotheses, such as the presence of pneumatoceles or cysts in COVID-19 patients in the absence of any mechanical ventilation, two cases have been reported of patients with cystic lung lesions linked to COVID-19, one of which was complicated by a pneumothorax 10 . Which is similar to cases of spontaneous pneumothorax in HIV patients and PJP pneumonia 11 . Another case describes a patient with no underlying lung pathology who developed a giant emphysematous bulla during COVID-19 pneumonia, which ended up bursting and causing a pneumothorax 5 . Moreover, none of the cases described were under mechanical ventilation, which suggests that the barotrauma associated with positive pressure ventilation cannot explain the formation of cysts that may subsequently lead to a secondary pneumothorax 4, 10 . In our case, none of the 2 infants underwent mechanical ventilation, which a barotrauma as a cause of the pneumothorax.

Another hypothesis incriminates prolonged coughing as a possible trigger, which is a common symptom of COVID-19 12, 13 , and could increase intra-thoracic pressure leading to a pneumothorax in the presence of alveolar damage due to COVID-19 pneumonia-related inflammation or ischemic parenchymal injury 14, 15 . This mechanism could explain the pneumothorax in our second case.

In our case, the 2 infants presented lymphopenia, elevated reactive protein C, LDH, ferritin and D-dimers levels, as well as interleukin 6 ( Table 1 ). These inflammation biomarkers suggest a significant inflammatory state and therefore a more severe pulmonary damage 16 .

Indeed, recently published studies on the mechanisms of pulmonary lesions induced by COVID-19 assume that the hyperactivity and deregulation of the immune response during the cytokine storm is responsible for more severe lung injuries 17 . In fact a high inflammatory state in COVID-19 adult patients suffering from a primary pneumothorax has been reported to the literature 18 The occurrence of a pneumothorax in COVID-19 patients has been considered a marker of grave prognosis 9, 19 . However, none of our patients died from their respiratory injury. Our case series therefore aligns with the largest multicenter case series published to date on pneumothorax in COVID-19 8 among other studies.

Spontaneous pneumothorax is a rare complication of COVID-19. It can occur at any time during the disease.

As information around COVID-19 in children continues to evolve, we highlight an important life-threatening complication associated with severe COVID-19 in infancy. Our case report is particularly interesting because it draws attention to the importance of considering a pneumothorax in infants in front of a respiratory aggravation or a persistent hypoxia even in the absence of mechanical ventilation.

This work is reported in line with the 2020 SCARE guidelines 20 J o u r n a l P r e -p r o o f

Written informed consent was obtained from the parents (given that our patients are minors) for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request Provenance and peer review Not commissioned, externally peer reviewed. 

The following information is required for submission. Please note that failure to respond to these questions/statements will mean your submission will be returned. If you have nothing to declare in any of these categories then this should be stated.

All authors must disclose any financial and personal relationships with other people or organisations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding.

We have no conflicts of interest Please state any sources of funding for your research All sources of funding should be declared as an acknowledgement at the end of the text. Authors should declare the role of study sponsors, if any, in the collection, analysis and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication. If the study sponsors had no such involvement, the authors should so state.

Research studies involving patients require ethical approval. Please state whether approval has been given, name the relevant ethics committee and the state the reference number for their judgement. This is a case report, therefore Ethics committee/IRB approval is not required.

J o u r n a l P r e -p r o o f Consent Studies on patients or volunteers require ethics committee approval and fully informed written consent which should be documented in the paper.

Authors must obtain written and signed consent to publish a case report from the patient (or, where applicable, the patient's guardian or next of kin) prior to submission. We ask Authors to confirm as part of the submission process that such consent has been obtained, and the manuscript must include a statement to this effect in a consent section at the end of the manuscript, as follows: "Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request".

Patients have a right to privacy. Patients' and volunteers' names, initials, or hospital numbers should not be used. Images of patients or volunteers should not be used unless the information is essential for scientific purposes and explicit permission has been given as part of the consent. If such consent is made subject to any conditions, the Editor in Chief must be made aware of all such conditions. Even where consent has been given, identifying details should be omitted if they are not essential. If identifying characteristics are altered to protect anonymity, such as in genetic pedigrees, authors should provide assurance that alterations do not distort scientific meaning and editors should so note.

Written informed consent was obtained from the parents (given that our patients are minors) for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Susceptibility to SARS-CoV-2 Infection Among Children and Adolescents Compared With Adults: A Systematic Review and Meta-analysis

COVID-19 with spontaneous pneumomediastinum

Mediastinal Emphysema, Giant Bulla, and Pneumothorax Developed during the Course of COVID-19 Pneumonia

Management of spontaneous pneumothorax: British Thoracic Society pleural disease guideline 2010

Spontaneous pneumothorax

COVID-19 and pneumothorax: a multicentre retrospective case series

Severe acute respiratory syndrome complicated by spontaneous pneumothorax

COVID-19 with cystic features on computed tomography: A case report

Pneumothorax with Pneumocystis carinii pneumonia in AIDS. Incidence and clinical characteristics

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Clinical Characteristics of Coronavirus Disease 2019 in China

Late-stage adult respiratory distress syndrome caused by severe acute respiratory syndrome: abnormal findings at thin-section CT

Characteristics of COVID-19 infection in Beijing

Dysregulation of Immune Response in Patients With Coronavirus

The pathogenesis and treatment of the `Cytokine Storm' in COVID-19

Pneumothorax In Covid-19 Pneumonia: A case series

Pneumomediastinum and spontaneous pneumothorax as an extrapulmonary complication of COVID-19 disease

The SCARE 2020 Guideline: Updating Consensus Surgical CAse REport (SCARE) Guidelines

Please specify the contribution of each author to the paper, e.g. study concept or design, data collection, data analysis or interpretation, writing the paper, others, who have contributed in other ways should be listed as contributors.ILYASS LAARIBI: study conception, data collection and analysis, writing and editing HAMZA MIMOUNI: data collection and analysis ZAKARIA BOUAYED: data analysis and writing GHIZLANE EL AIDOUNI: contributor SAMIA BERRICHI: contributor CHOUKRI BAHOUH: contributor HOUSSAM BKIYAR: Supervision and review data validation. HOUSNI BRAHIM: Supervision and review data validation.

In accordance with the Declaration of Helsinki 2013, all research involving human participants has to be registered in a publicly accessible database. Please enter the name of the registry and the unique identifying number (UIN) of your study.You can register any type of research at http://www.researchregistry.com to obtain your UIN if you have not already registered. This is mandatory for human studies only. Trials and certain observational research can also be registered elsewhere such as: ClinicalTrials.gov or ISRCTN or numerous other registries.

Name of the registry:2. Unique Identifying number or registration ID:3.Hyperlink to your specific registration (must be publicly accessible and will be checked):

The Guarantor is the one or more people who accept full responsibility for the work and/or the conduct of the study, had access to the data, and controlled the decision to publish ILYASS LAARIBI J o u r n a l P r e -p r o o f